BRCA1 and cancer: This has been studied extensively in the preclinical and clinical setting in cancers harboring BRCA1/2 mutations, which induce homologous recombination deficiency (HRD), leading to a reliance on other compensatory DDR pathways such as BER and NHEJ [17].